Design, synthesis, and evaluation of novel anti-trypanosomal compounds

Human African trypanosomiasis (HAT) is a deadly neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. During the course of screening a collection of diverse nitrogenous heterocycles, we discovered two novel compounds that contain the tetracyclic core of the Yohimbine and Co...

Full description

Saved in:
Bibliographic Details
Published inTetrahedron Vol. 76; no. 16; pp. 131086 - 131094
Main Authors Lepovitz, Lance T., Meis, Alan R., Thomas, Sarah M., Wiedeman, Justin, Pham, Alexandra, Mensa-Wilmot, Kojo, Martin, Stephen F.
Format Journal Article
LanguageEnglish
Published OXFORD Elsevier Ltd 17.04.2020
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Human African trypanosomiasis (HAT) is a deadly neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. During the course of screening a collection of diverse nitrogenous heterocycles, we discovered two novel compounds that contain the tetracyclic core of the Yohimbine and Corynanthe alkaloids, were potent inhibitors of T. brucei proliferation and T. brucei methionyl-tRNA synthetase (TbMetRS) activity. Inspired by these key findings, we prepared several novel series of hydroxyalkyl δ-lactam, δ-lactam, and piperidine analogs and tested their anti-trypanosomal activity. A number of inhibitors were more potent against T. brucei than these initial hits with one hydroxyalkyl δ-lactam derivative being 25-fold more effective in our assay. Surprisingly, most of these active compounds failed to inhibit TbMetRS. This work underscores the importance of verifying, irrespective of close structural similarities, that new compounds designed from a lead with a known biological target engage the putative binding site. [Display omitted]
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0040-4020
1464-5416
DOI:10.1016/j.tet.2020.131086